EKR Therapeutics Names Two Independent Directors and Reaffirms Board of Directors to Lead Company Growth in the Critical C

BEDMINSTER, N.J.--(BUSINESS WIRE)-- EKR Therapeutics, Inc., a privately held specialty pharmaceutical company focused on providing critical care products to the hospital marketplace, has announced the appointment of Robert S. Whitehead and Joseph M. Mahady to the EKR Board as Independent Directors. On October 21, 2011, Robert P. Roche, Jr. was previously named as an Independent Director. In addition, all previous Board Members were reelected at EKR’s November 8th Annual Meeting of Stockholders.

“We are pleased to welcome Bob Roche, Bob Whitehead and Joe Mahady to our Board,” says John Bailye, CEO of EKR Therapeutics. “Each comes to EKR with a wealth of experience in pharmaceutical commercial operations, sales and marketing, and pipeline-building. Their long and distinguished careers in our industry, in both the private and public sectors, brings additional breadth and expertise to our Board.”

Mr. Whitehead is President, CEO and founder of Slate Pharmaceuticals, Inc., a specialty pharmaceutical company focused in the field of urology. He was previously President and COO of Auxilium Pharmaceuticals, and has held senior executive roles at a number of pharmaceutical companies, including Prestwick Pharmaceuticals, ZymoGenetics Inc., Dura Pharmaceuticals/Élan Pharmaceuticals, and Marion Laboratories.

Mr. Mahady joins the EKR Board after an illustrious career at Wyeth, a Fortune 110 pharma/biotech company. During his 30+ year tenure there, Joe served as President of various business units, culminating as President of Wyeth Pharmaceuticals. He brings to EKR deep strategic and operational expertise.

Mr. Roche brings to EKR the experiences of a distinguished career in the pharmaceutical industry. Prior roles include Executive Vice President, Worldwide Pharmaceutical Operations at Cephalon, Inc., a global biopharmaceutical company, and a variety of sales and marketing positions at SmithKline Beecham.

“This is a time of important transition for our company, and I welcome having Bob, Bob and Joe help guide our vision for the future,” says Mr. Bailye.

In addition, all six incumbent Board Members were reelected: John Bailye, who has served as CEO since 2010; Zev Scherl who joined the Board in 2006; Doug Sheldon who has served since 2006; Adele Oliva, a director since 2007; Steven St. Peter and Scott Perricelli, who both have served since 2008.

About EKR Therapeutics, Inc

Since its inception, EKR has focused on acute-care hospital products and continues to actively pursue new opportunities in the hospital space. With its experienced field force of sales professionals, along with its commitment to excellence in customer service and medical education, EKR is leading the way as a provider of acute-care specialty products.

For additional information about EKR, visit the company’s website at www.ekrtx.com.



CONTACT:

Media:
EKR Therapeutics
Jen Zuccolo, 877-435-2524

KEYWORDS:   United States  North America  New Jersey

INDUSTRY KEYWORDS:   Surgery  Practice Management  Health  Biotechnology  Hospitals  Medical Devices  Pharmaceutical  Nursing

MEDIA:

Logo
 Logo

Suggested Articles

Two weeks after receiving a second dose of Moderna's COVID-19 jab, patients had "robust" levels of neutralizing antibodies against the…

Despite questions about eye-related side effects, GlaxoSmithKline's anti-BCMA treatment emerged from an advisory committee meeting with a 12-0 vote.

After Mallinckrodt's terlipressin beat placebo at reversing kidney failure, an FDA panel will discuss the phase 3 trial's surrogate endpoint.